


MAIN FIGURES



% Geographic distribution in 2024



1. Adjusted EBITDA 2023: Earnings before interest, taxes, depreciation and amortization deducting extraordinary expenses derived from the Miralta process and the search for advisors (advisors for the entire process) Adjusted EBITDA 2024: Earnings before interest, taxes, depreciation and amortization deducting extraordinary expenses derived from the Miralta process, the divestment process in Serbia and the search for financing. 2. Net Financial Debt at 31.12.2024.
2023 data without Zavod non-audited.

LABIANA PHARMA: MAIN FIGURES



Turnover

€34.4M

Var. 2023 without Zavod: 15.8%



% Own Vademecum

16.9%

Var. 2023 without Zavod: (2.5) p.p.



% CDMO

35.0%

Var. 2023 without Zavod: 1.4 p.p.



177
Employees




101
MAAs



Main products

Fosfomicin
Trometamol

Precyst



LABIANA LIFE: MAIN FIGURES



Turnover

€31.8M

Var. 2023 without Zavod: 21.3%



% Own Vademecum

15.2%

Var. 2023 without Zavod: (0.6) p.p.



% CDMO

32.8%

Var. 2023 without Zavod: 1.7 p.p.



Main products

Labiprofen



Labimycin



Tolfelab



Buprelab



Tilolab



193

Employees



496

MAs

Financial data with regarding total turnover for fiscal year 2024. 2023 data without Zavod non-audited.